Vertex Pharmaceuticals Incorpor (VRTX) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$4.73

Estimate

$4.75

Surprise

-0.3%

Score at report (before → after)

6.3 → 6.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Vertex Pharmaceuticals Incorpor (VRTX) missed the $4.75 estimate with diluted EPS of $4.73 — effectively in line (0.3%). TrendMatrix's engine moved from Hold (6.3/10) to Buy (Wait) at 6.3/10 after the report.

TrendMatrix currently rates VRTX Hold at 5.6/10.

2 of the last 4 quarters beat the estimate; this quarter's -0.3% surprise compares with a +1.5% four-quarter average. Next scheduled report: 2026-11-02.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$546.82

Price target

$628.83

Stop

$522.17

Upside to target

+15.0%

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$141.42B

P/E (fwd)

25.6

P/E (ttm)

32.5

52-week range

$374.17–$560.25

Off 52-week high

2.4%

RSI (14)

65

Volume vs avg

0.34×

Score today

5.6/10